-
Mashup Score: 0
Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med 2023;388:1080-91.
Source: www.jaci-inpractice.orgCategories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0
April 11, 2023 — A newly-published study in the Journal of the American College of Cardiology, JACC, the flagship journal of the American College of Cardiology (ACC), focuses on the impact of moderate exercise in patients using statins. It offers reassuring findings for people who experience muscle pain or fatigue from statins but need to engage in physical activity to keep their cholesterol…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor @JACCJournals A newly-published study in the Journal of the American College of Cardiology (#JACC), focused on the impact of #moderate #exercise in #patients using #statins: https://t.co/XBsH2jD2y4
-
-
Mashup Score: 1Efficacy of Dupilumab in Patients with Moderate-to-Severe Asthma and Persistent Airflow Obstruction - PubMed - 1 year(s) ago
In patients with uncontrolled moderate-to-severe asthma, treatment with dupilumab facilitates reversal of PAO status and improves clinical outcomes.
Source: PubMedCategories: Latest Headlines, PulmonologyTweet-
Efficacy of #Dupilumab in Patients with #Moderate-to- #Severe #Asthma and #Persistent #Airflow #Obstruction https://t.co/3O007GVd6F https://t.co/PNLV0VhP18
-
-
Mashup Score: 0Dupilumab Is Effective in Patients With Moderate-to-Severe Uncontrolled GINA-Defined Type 2 Asthma Irrespective of an Allergic Asthma Phenotype - 1 year(s) ago
The Global Initiative for Asthma report recommends consideration of add-on biologics for patients with type 2 inflammation (blood eosinophils ≥150 cells/μL, fractional exhaled nitric oxide [Feno] ≥20 parts per billion or allergic asthma) whose asthma cannot be controlled by high-dose inhaled corticosteroids. In QUEST (NCT02414854), add-on dupilumab versus placebo was efficacious in patients with…
Categories: Allergy-Immunology, Latest HeadlinesTweet-
In Current Issue! #Dupilumab Is #Effective in #Patients With #Moderate-to- #Severe Uncontrolled #GINA-Defined #Type2 #Asthma #Irrespective of an #Allergic #Asthma #Phenotype https://t.co/n4pwHBWEMP https://t.co/kP0B1hvWov
-
-
Mashup Score: 2
Asthma patients remain susceptible to severe exacerbations even when their condition is seemingly brought under control,1 potentially suggesting an element of disconnect between exacerbations and asthma control. It has recently been shown that combining oscillometry and spirometry measurements of pulmonary function identifies patients with worse asthma control and more frequent severe…
Categories: Allergy-Immunology, Latest HeadlinesTweet-
In Current Issue! #Determinants of #asthma #control and #exacerbations in #moderate to #severe #asthma https://t.co/LwVSevHShl https://t.co/sbpBSS50ob
-
-
Mashup Score: 3Constant-Load Exercise Versus High-Intensity Interval Training on Aerobic Fitness in Moderate-to-Severe Asthma: A Randomized Controlled Trial - 2 year(s) ago
The effects of high-intensity interval training (HIIT) on dyspnea and aerobic fitness in adults with asthma are poorly understood.
Categories: Allergy-Immunology, Latest HeadlinesTweet-
In Current Issue! #Constant- #Load #Exercise #Versus #High- #Intensity #Interval Training on #Aerobic #Fitness in #Moderate-to- #Severe #Asthma: A Randomized Controlled Trial https://t.co/ts4ER7Hjt6 https://t.co/EMbQtRERPV
-
-
Mashup Score: 4
Mucus plugging (MP) is recognised as a contributory factor to airway obstruction and symptoms in persistent asthma.
Categories: Allergy-Immunology, Latest HeadlinesTweet-
In Press! #Clinical #associations of #mucus #plugging in #moderate to #severe #asthma https://t.co/Os9Bm8QzgP
-
-
Mashup Score: 3Dupilumab Improves Clinical Scores in Children and Adolescents With Moderate to Severe Atopic Dermatitis: A Real-World, Single-Center Study - 2 year(s) ago
Dupilumab has proven safe and effective in children and adolescents with atopic dermatitis (AD) in clinical trials. However, comprehensive real-world studies in the pediatric AD population are still needed.
Categories: Allergy-Immunology, Latest HeadlinesTweet-
In Current Issue! #Dupilumab Improves #Clinical #Scores in #Children and #Adolescents With #Moderate to #Severe #Atopic #Dermatitis: A Real-World, Single-Center Study https://t.co/30TYEWMsJP https://t.co/V6DCyK0Ez5
-
-
Mashup Score: 0Factors Related to Biologic Adherence and Outcomes Among Moderate-to-Severe Asthma Patients - 2 year(s) ago
Adherence barriers to asthma biologics may not be uniform across administration settings for patients with moderate-to-severe asthma.
Categories: Allergy-Immunology, Latest HeadlinesTweet-
In Current Issue! Factors Related to #Biologic #Adherence and #Outcomes #Among #Moderate-to- #Severe #Asthma #Patients https://t.co/umWhOqsuyi https://t.co/zYuVDCHyOg
-
-
Mashup Score: 1Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthma - PubMed - 2 year(s) ago
Dupilumab treatment led to improvements in lung function independent of exacerbations and appeared to reduce the impact of exacerbations on lung function in patients who experienced a severe exacerbation during the study.
Source: PubMedCategories: Latest Headlines, PulmonologyTweet-
#Dupilumab reduced impact of #severe #exacerbations on #lung #function in patients with #moderate-to- #severe #type 2 #asthma https://t.co/Far0Gxz492 https://t.co/Sflea7JUpO
-
In Current Issue! #Lebrikizumab #Monotherapy for the #Treatment of #Moderate to #Severe #Atopic #Dermatitis https://t.co/co5pSrVnXS https://t.co/o3LH8u4NjS